Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Primary Sclerosing Cholangitis
Interventions: NGM282, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 26
States / cities: Sacramento, California • San Clemente, California • San Francisco, California + 21 more

Conditions: Pulmonary Arterial Hypertension
Interventions: GB002, Placebo, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: La Jolla, California • Sacramento, California • Aurora, Colorado + 9 more

Conditions: Cancer, Giant Cell Tumors, Giant Cell Tumor of Bone, Benign Giant Cell Tumors
Interventions: Denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 11
States / cities: Santa Monica, California • Stanford, California • Washington D.C., District of Columbia + 7 more

Conditions: Leukemia
Interventions: nilotinib, cytogenetic analysis, mutation analysis, polymerase chain reaction, pharmacological study; Drug · Genetic · Other
Lead sponsor: Cancer Trials Ireland; Network
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Patients With Chemotherapy-Induced Thrombocytopenia
Interventions: Hetrombopag Olamine, Hetrombopag Olamine; Hetrombopag Olamine Placebo; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 14
States / cities: Long Beach, California • Los Alamitos, California • Los Angeles, California + 11 more

Conditions: Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
Interventions: Xtressé Hair Growth Gummies, Placebo Comparator; Other · Dietary Supplement
Lead sponsor: Restore Biologics Holdings, Inc. dba Xtressé; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Maitland, Florida • Port Orange, Florida

Conditions: Oligometastatic Prostate Cancer (OMPC)
Interventions: AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 39
States / cities: Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Idiopathic Short Stature
Interventions: Genotropin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Years to 10 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 43
States / cities: Little Rock, Alaska • Little Rock, Arkansas • Los Angeles, California + 32 more

Conditions: Breast Cancer
Interventions: Exemestane + Dasatinib, Exemestane + Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Fountain Valley, California • Riverside, California • Philadelphia, Pennsylvania + 1 more

Conditions: Hepatorenal Syndrome
Interventions: Terlipressin, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Partial Onset Seizures
Interventions: Investigational new drug, company code: BGG492, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 10 more

Conditions: Chest Wrinkles
Interventions: Ulthera System Treatment; Device
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Sacramento, California • San Diego, California • Chicago, Illinois + 1 more

Conditions: Alzheimer's Disease
Interventions: [F-18]W372; Drug
Lead sponsor: Siemens Molecular Imaging; Industry
Eligibility: 55 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Irvine, California

Conditions: Pulmonary Disease
Interventions: Progel® Pleural Air Leak Sealant; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Jacksonville, Florida • Jupiter, Florida • Miami, Florida + 11 more

Conditions: KRAS Gene Mutation
Interventions: TVB-2640; Drug
Lead sponsor: David E Gerber; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Cincinnati, Ohio • Dallas, Texas

Conditions: MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions: Resmetirom, Placebo; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Peoria, Arizona • Oxnard, California • Fort Myers, Florida + 2 more

Conditions: Colitis, Ulcerative
Interventions: Etrasimod; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 26
States / cities: Mesa, Arizona • La Jolla, California • Los Alamitos, California + 20 more

Conditions: Bowel Preparation
Interventions: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution, Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 917 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 12
States / cities: Huntsville, Alabama • Anaheim, California • Chula Vista, California + 9 more

Conditions: Biliary Tract Cancer
Interventions: Rucaparib, Nivolumab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee

Conditions: Coronary Artery Disease
Interventions: 64 Channel VCT; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Waukesha, Wisconsin

Conditions: Polycystic Kidney Disease, Autosomal Dominant
Interventions: Tolvaptan, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 1,445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 30
States / cities: Mobile, Alabama • Riverside, California • Stanford, California + 23 more

Conditions: Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection
Interventions: NeuMoDx CT/NG Assay, FDA-cleared NAATs; Diagnostic Test
Lead sponsor: NeuMoDx Molecular, Inc.; Industry
Eligibility: 14 Years to 80 Years
Enrollment: 4,017 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • North Miami, Florida • Orlando, Florida + 12 more

Conditions: Triple Negative Breast Cancer
Interventions: Pembrolizumab, INBRX-106; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • Portland, Oregon

Conditions: Sunscreen
Interventions: Sunscreen A, Sunscreen B, Sunscreen C, Sunscreen D, Sunscreen E, Sunscreen F; Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Teaneck, New Jersey

Search by objective public record fields.

A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)

Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

Evaluation of the Ulthera System for the Treatment of the Decolletage

Exploratory and Safety Study of [F-18]W372

Progel® Pleural Air Leak Sealant (PALS) in Video and Robotic Assisted Thoracoscopic Surgery

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

Resmetirom in Patients With MASH and HFpEF

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Perfusion Imaging and CT -Understanding Relative Efficacy

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NeuMoDx PrEDiCTiNG Study Evaluation Plan

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

A Study to Evaluate the Whitening Effect of Mineral Sunscreens in Multi-Cultural Skin Tones